MEDP - Medpace Hldgs Insider Trades Send A Signal | Benzinga
Making a noteworthy insider sell on May 1, August J Troendle, CEO at Medpace Hldgs (NASDAQ:MEDP), is reported in the latest SEC filing.
What Happened: Troendle's recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday unveiled the sale of 16,930 shares of Medpace Hldgs. The total transaction value is $6,782,987.
Monitoring the market, Medpace Hldgs's shares down by 0.0% at $397.86 during Thursday's morning.
Unveiling the Story Behind Medpace Hldgs
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Key Indicators: Medpace Hldgs's Financial Health
Revenue Growth: Medpace Hldgs's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate ...